ImmunityBio Shares Maintain Upward Momentum on Clinical and Commercial Progress

The biotechnology firm ImmunityBio continues to capture significant investor attention in early 2026, propelled by a series of strategic developments. Following encouraging regulatory feedback and robust commercial figures, the company has now initiated a key Phase 2 clinical trial. This study, launched on a Monday, aims to validate a chemotherapy-free treatment regimen for lymphoma, adding to the dynamic news flow that has substantially boosted the company's market valuation in recent months.

The clinical advances are supported by compelling operational performance. In mid-January, ImmunityBio reported preliminary annual revenue for its flagship product, ANKTIVA, reaching approximately $113 million. This figure represents a surge of nearly 700% compared to the prior year, confirming strong market adoption.

On the regulatory front, a meeting with the U.S. Food and Drug Administration (FDA) on January 20th paved the way for the resubmission of a label expansion for bladder cancer treatment. Critically, this pathway does not require new, time-consuming clinical trials. The company's international footprint is also growing, with recent approval for ANKTIVA to treat bladder and lung cancer granted by Saudi Arabia's Food and Drug Authority.

A Strategic Shift Toward Gentler Treatments

The newly commenced "ResQ215B" trial is central to the company's pipeline strategy. It evaluates a combination of the company's natural killer cell therapy and ANKTIVA in patients with B-cell non-Hodgkin lymphoma. The defining feature of this approach is its elimination of chemotherapy.

Should investors sell immediately? Or is it worth buying ImmunityBio?

This method contrasts with conventional CAR-T therapies, which typically demand intensive pretreatment and complex logistics. The new protocol is designed for outpatient administration, requiring neither an elaborate cell collection process nor a hospital stay. The trial builds on promising Phase 1 data that demonstrated a 100% disease control rate within a small patient cohort.

Capital Structure and Forthcoming Catalysts

Alongside its clinical and commercial execution, management is actively optimizing the balance sheet. A modification to the $505 million convertible note held by Nant Capital now permits the partial conversion of debt into equity. This adjustment provides the company with enhanced financial flexibility to support its ongoing expansion.

Investors are now looking ahead to the next major milestone: the detailed earnings report expected in early March. This release will allow the market to verify the preliminary sales figures and scrutinize the specific timeline management provides for the upcoming FDA submission.

The convergence of these clinical, commercial, and financial successes is reflected in the equity's performance. Since the start of the year, ImmunityBio shares have advanced more than 200%, with the stock currently trading at $6.13.